<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="79480"><DrugName>somatropin biosimilar, Sandoz</DrugName><DrugNamesKey><Name id="42985724">Omnitrope</Name><Name id="43066107">PrOmnitrope</Name><Name id="42989340">Somatropin BS S.C. injection 5mg / 10mg (Sandoz)</Name><Name id="42756682">somatropin</Name></DrugNamesKey><DrugSynonyms><Name><Value>somatropin</Value><Types><Type>USAN</Type><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>Omnitrope</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>somatropin biosimilar, Sandoz</Value></Name><Name><Value>Somatropin BS S.C. injection 5mg / 10mg (Sandoz)</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>PrOmnitrope</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1017404">Sandoz International GmbH</CompanyOriginator><CompaniesPrimary><Company id="1017404">Sandoz International GmbH</Company></CompaniesPrimary><CrossReferences><SourceEntity id="79480" type="Drug"><TargetEntity id="685211" type="siDrug">Recombinant somatropin</TargetEntity></SourceEntity><SourceEntity id="1017404" type="Company"><TargetEntity id="5000072957" type="organizationId">Sandoz International GmbH</TargetEntity></SourceEntity><SourceEntity id="140" type="ciIndication"><TargetEntity id="D006130" type="MeSH"/><TargetEntity id="1100" type="siCondition"/></SourceEntity><SourceEntity id="2535" type="ciIndication"><TargetEntity id="10056438" type="MEDDRA"/><TargetEntity id="D004393" type="MeSH"/><TargetEntity id="516" type="siCondition"/><TargetEntity id="1820" type="siCondition"/></SourceEntity><SourceEntity id="2890" type="ciIndication"><TargetEntity id="10036476" type="MEDDRA"/><TargetEntity id="D011218" type="MeSH"/><TargetEntity id="739" type="ORPHANET"/><TargetEntity id="-1588080614" type="omicsDisease"/><TargetEntity id="1747" type="siCondition"/></SourceEntity><SourceEntity id="195" type="Action"><TargetEntity id="580" type="Mechanism">Growth Hormone Secretagogues</TargetEntity></SourceEntity><SourceEntity id="PTGT-00889" type="ciTarget"><TargetEntity id="211402913826903" type="siTarget">Growth hormone receptor</TargetEntity><TargetEntity id="306" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-04782" type="ciTarget"><TargetEntity id="111540190526883" type="siTarget">Somatotropin</TargetEntity><TargetEntity id="305" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Growth disorder - Australia - Nov-2005</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="140">Growth disorder</Indication><Indication id="2535">Growth hormone deficiency</Indication><Indication id="2890">Prader-Willi syndrome</Indication></IndicationsPrimary><ActionsPrimary><Action id="195">Growth hormone receptor agonist</Action><Action id="21072">Growth hormone ligand</Action></ActionsPrimary><Technologies><Technology id="85">Protein recombinant</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="894">Liquid formulation</Technology><Technology id="962">Biosimilar product</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>H4C</Code><Name>GROWTH HORMONES</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-17T08:37:57.000Z</LastModificationDate><ChangeDateLast>2019-06-19T00:00:00.000Z</ChangeDateLast><AddedDate>2012-07-19T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1017404" linkType="Company"&gt;Sandoz&lt;/ulink&gt; has developed Omnitrope (PrOmnitrope),  a biosimilar version of somatropin   (recombinant human growth hormone) synthesized in a strain of Escherichia coli,   for the long-term sc treatment of pediatric patients who have growth failure or idiopathic short stature (ISS), and long-term sc replacement therapy in adults with growth hormone deficiency (GHD) [&lt;ulink linkID="1309349" linkType="Reference"&gt;1309349&lt;/ulink&gt;], [&lt;ulink linkID="1309367" linkType="Reference"&gt;1309367&lt;/ulink&gt;], [&lt;ulink linkID="1309349" linkType="Reference"&gt;1309349&lt;/ulink&gt;],  [&lt;ulink linkID="1691393" linkType="Reference"&gt;1691393&lt;/ulink&gt;]. In November 2005, it was launched in Australia [&lt;ulink linkID="661362" linkType="Reference"&gt;661362&lt;/ulink&gt;]. In April 2006, the drug was approved in Denmark and subsequently launched [&lt;ulink linkID="1424386" linkType="Reference"&gt;1424386&lt;/ulink&gt;]; at that time, the drug was approved in the Netherlands and Latvia [&lt;ulink linkID="1456499" linkType="Reference"&gt;1456499&lt;/ulink&gt;],  [&lt;ulink linkID="1436150" linkType="Reference"&gt;1436150&lt;/ulink&gt;] and was subsequently launched in both the countries [&lt;ulink linkID="1454583" linkType="Reference"&gt;1454583&lt;/ulink&gt;], [&lt;ulink linkID="1436151" linkType="Reference"&gt;1436151&lt;/ulink&gt;]. By May 2006, it was available in Germany [&lt;ulink linkID="1309401" linkType="Reference"&gt;1309401&lt;/ulink&gt;].  Omnitrope was subsequently launched in the rest of the EU, including the UK [&lt;ulink linkID="1309607" linkType="Reference"&gt;1309607&lt;/ulink&gt;], [&lt;ulink linkID="1309672" linkType="Reference"&gt;1309672&lt;/ulink&gt;]. In June 2006, the drug was launched in Sweden [&lt;ulink linkID="1411505" linkType="Reference"&gt;1411505&lt;/ulink&gt;]. In January 2007, it was launched in the US [&lt;ulink linkID="1309349" linkType="Reference"&gt;1309349&lt;/ulink&gt;].  In  July  2007, Omnitrope was approved in Spain and was subsequently launched [&lt;ulink linkID="1363083" linkType="Reference"&gt;1363083&lt;/ulink&gt;]. In September 2007, the drug was approved in Slovakia and was subsequently launched [&lt;ulink linkID="1468910" linkType="Reference"&gt;1468910&lt;/ulink&gt;], [&lt;ulink linkID="1466334" linkType="Reference"&gt;1466334&lt;/ulink&gt;]. In October 2007, the drug was approved in Iceland [&lt;ulink linkID="1451736" linkType="Reference"&gt;1451736&lt;/ulink&gt;] and subsequently launched [&lt;ulink linkID="1450511" linkType="Reference"&gt;1450511&lt;/ulink&gt;]. In January 2008, the drug was launched in France [&lt;ulink linkID="1350516" linkType="Reference"&gt;1350516&lt;/ulink&gt;].  In October 2009, it was launched in Japan [&lt;ulink linkID="1309607" linkType="Reference"&gt;1309607&lt;/ulink&gt;].  It was launched in Taiwan, Argentina and the Czech Repulic in 2010 [&lt;ulink linkID="1309625" linkType="Reference"&gt;1309625&lt;/ulink&gt;] and presumably the same year in Canada [&lt;ulink linkID="1309668" linkType="Reference"&gt;1309668&lt;/ulink&gt;]. In November 2010, the drug was launched in Switzerland [&lt;ulink linkID="1596958" linkType="Reference"&gt;1596958&lt;/ulink&gt;]. In January 2011, the drug was launched in Norway [&lt;ulink linkID="1458539" linkType="Reference"&gt;1458539&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In August 2004, the FDA was unable to reach a decision on whether to approve the marketing application for Omnitrope. In September 2005, Sandoz filed a lawsuit against the FDA to seek a ruling on the pending application [&lt;ulink linkID="661362" linkType="Reference"&gt;661362&lt;/ulink&gt;]. The product was approved in the US in May 2006 under the 505(b)(2) pathway for the treatment of pediatric patients with growth failure and as a replacement therapy in adults with GHD, and was launched there in January 2007 [&lt;ulink linkID="1309349" linkType="Reference"&gt;1309349&lt;/ulink&gt;], [&lt;ulink linkID="1484863" linkType="Reference"&gt;1484863&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In June 2003, the CHMP of the EMA recommended that the EC grant marketing authorization for Omitrope, but the EC refused marketing authorization on legal grounds related to the selected approval pathway. In July 2004, Sandoz submitted a second application, which followed the new amended Annex to Directive 2001/83/EC, under recommendation from the EMA and the EC  [&lt;ulink linkID="661362" linkType="Reference"&gt;661362&lt;/ulink&gt;]. In April 2006,  the product was approved in the EU [&lt;ulink linkID="1309367" linkType="Reference"&gt;1309367&lt;/ulink&gt;]; at that time, the drug was approved in Denmark and subsequently launched [&lt;ulink linkID="1424386" linkType="Reference"&gt;1424386&lt;/ulink&gt;]; at that time, the drug was approved in the Netherlands and Latvia [&lt;ulink linkID="1456499" linkType="Reference"&gt;1456499&lt;/ulink&gt;],  [&lt;ulink linkID="1436150" linkType="Reference"&gt;1436150&lt;/ulink&gt;] and was subsequently launched in both the countries [&lt;ulink linkID="1454583" linkType="Reference"&gt;1454583&lt;/ulink&gt;], [&lt;ulink linkID="1436151" linkType="Reference"&gt;1436151&lt;/ulink&gt;].     It was available in Germany by May 2006; at that time, launches were planned for additional countries in the EU [&lt;ulink linkID="1309401" linkType="Reference"&gt;1309401&lt;/ulink&gt;].  In June 2006, the drug was launched in Sweden [&lt;ulink linkID="1411505" linkType="Reference"&gt;1411505&lt;/ulink&gt;]. In  July  2007, Omnitrope was approved in Spain and was subsequently launched [&lt;ulink linkID="1363083" linkType="Reference"&gt;1363083&lt;/ulink&gt;]. In September 2007, the drug was approved in Slovakia and was subsequently launched [&lt;ulink linkID="1468910" linkType="Reference"&gt;1468910&lt;/ulink&gt;], [&lt;ulink linkID="1466334" linkType="Reference"&gt;1466334&lt;/ulink&gt;]. In October 2007, the drug was approved in Iceland [&lt;ulink linkID="1451736" linkType="Reference"&gt;1451736&lt;/ulink&gt;] and subsequently launched [&lt;ulink linkID="1450511" linkType="Reference"&gt;1450511&lt;/ulink&gt;]. In January 2008, the drug was launched in France [&lt;ulink linkID="1350516" linkType="Reference"&gt;1350516&lt;/ulink&gt;]. In November 2010, the drug was launched in Switzerland [&lt;ulink linkID="1596958" linkType="Reference"&gt;1596958&lt;/ulink&gt;]. In January 2011, the drug was launched in Norway [&lt;ulink linkID="1458539" linkType="Reference"&gt;1458539&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By the end of 2010, it had been launched in Czech Repulic [&lt;ulink linkID="1309625" linkType="Reference"&gt;1309625&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In June 2009, it was approved in Japan as Somatropin BS S.C. injection 5mg / 10mg (Sandoz) [&lt;ulink linkID="1317907" linkType="Reference"&gt;1317907&lt;/ulink&gt;]. In October 2009, the drug was launched in Japan [&lt;ulink linkID="1309607" linkType="Reference"&gt;1309607&lt;/ulink&gt;]. In August 2013, the drug was approved for additional indications of children with short statue due to Prader-Willi Syndrome without epiphyseal closure and small for gestational age [&lt;ulink linkID="1477501" linkType="Reference"&gt;1477501&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the World&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;By August 2010, Omnitrope had been approved in Canada [&lt;ulink linkID="1309349" linkType="Reference"&gt;1309349&lt;/ulink&gt;]. It was also launched in Canada, presumably in the same year [&lt;ulink linkID="1309668" linkType="Reference"&gt;1309668&lt;/ulink&gt;]. In September 2015, Health Canada approved the product for   a number of additional indications, including growth failure in  short children  born small for gestational age, short stature associated with Turner syndrome,   and long-term treatment of idiopathic short stature (in children) and indications, including adult and childhood onset growth hormone deficiency  (in adults) [&lt;ulink linkID="1691393" linkType="Reference"&gt;1691393&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By the end of 2010, the drug had been launched in Argentina [&lt;ulink linkID="1309625" linkType="Reference"&gt;1309625&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In September 2004, Omnitrope was approved in  Australia for the treatment of growth disorders in children; in November 2005,  it was launched there  [&lt;ulink linkID="661362" linkType="Reference"&gt;661362&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2010, Omnitrope had been approved in Taiwan [&lt;ulink linkID="1309349" linkType="Reference"&gt;1309349&lt;/ulink&gt;]. By the end of 2010, it had been launched in Taiwan [&lt;ulink linkID="1309625" linkType="Reference"&gt;1309625&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In March 2019, interim data from an ongoing, prospective, open-label, non-comparative, multicenter, long-term, phase IV study conducted in 32 centers across seven countries which evaluated the safety and efficacy of Omnitrope in short children born small for gestational age (n = 132) were presented at the 2019 Endocrine Society Annual Meeting in New Orleans, LA. Mean 2 h oral glucose tolerance test (5.43, 5.35, and 5.43 mM at year one, two and at latest visit), HbA1c (5.37, 5.37 and 5.29%) and fasting glucose levels (4.65, 4.69 and 4.75 mM) were maintained relatively stable from baseline up to latest visit. In contrast, mean fasting insulin levels (53.68, 60.27 and 70.46 pM at year one, two and at latest visit) and homeostasis model assessment scores (1.57, 1.74 and 2.14 at year one, two and at latest visit) progressively increased from baseline to each subsequent time point. Serious AEs (125 events) were reported in 68 patients; ear infection, adenoid hypertrophy, brain stem glioma and headache were four such events related to study drug. Auxological data showed that Omnitrope treatment was effective, with continued improvements in height parameters from baseline to the latest visit  [&lt;ulink linkID="2131132" linkType="Reference"&gt;2131132&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2019, data from an ongoing, international, multicenter, non-interventional, longitudinal long-term phase IV study (PATRO) conducted across 14 different countries which evaluated the long-term safety and efficacy of Omnitrope children with GHD from the US (n = 294) and Rest of World (ROW; n = 6500) were presented at the 2019 Endocrine Society Annual Meeting in New Orleans, LA. Mean duration of Omnitrope treatment was 40.24 and 38.18 months in US and ROW patients, respectively. In total, 886 AEs were reported in 194 patients of US; 5 AEs reported in five patients were treatment-related AEs (TRAEs). Discontinuation in treatment due to AEs was reported in three patients. For ROW, 11716 AEs were reported in 2977 patients, 636 AEs were TRAEs and 105 discontinued the study treatment due to AEs. Serious AEs were reported in 14 US patients and 738 ROW patients (19 and 1429 events, respectively); 1 US patient and 49 ROW patients  with SAEs were drug-related  [&lt;ulink linkID="2131142" linkType="Reference"&gt;2131142&lt;/ulink&gt;]. In April 2019, further data from US patients were presented at the 2019 Pediatric Academic Societies Annual Meeting in Baltimore, MD. Patients showed no clinically relevant anti-hGH antibody titers. In most of the patients, rhGH treatment showed a positive impact on growth parameter. Following three years of treatment, improvement in height standard deviation score and height velocity standard deviation score from baseline was 1.3 and 3.1 in prepubertal treatment-naive GHD patients, and 1.2 and 4.3 in ISS patients, respectively.  [&lt;ulink linkID="2160688" linkType="Reference"&gt;2160688&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In June 2014, clinical data were presented from the an observational, multicenter, open, longtitudinal study (PATRO Adults) at the 16th ICE/96th ENDO Joint conference in Chicago, IL. The number of suspected drug-related adverse events was 53, and these occurred in 36 patients and included worsening of diabetes mellitus and moderate intensity hepatic neoplasm. None of the three fatal cases (brain cell glioma, lung neoplasm, and unknown cause) reported were considered to be related to treatment and 13 of 56 patients discontinuing treatment did so due to adverse events [&lt;ulink linkID="1570615" linkType="Reference"&gt;1570615&lt;/ulink&gt;], [&lt;ulink linkID="1571963" linkType="Reference"&gt;1571963&lt;/ulink&gt;]. In May 2015, further clinical data were presented at the ECE 2015 in Dublin, Ireland. A total of 109 serious adverse events were reported and 1079 were most adverse events (AEs) were mild to moderate in intensity. Headache, myalgia, edema peripheral and arthralgia were some of the most frequently reported drug-related AEs. Treatment with omnitrope was found to be well tolerated [&lt;ulink linkID="1673919" linkType="Reference"&gt;1673919&lt;/ulink&gt;]. In April 2016, interim analysis clinical data were presented at the 98th Endocrine Society Annual Meeting in Boston, MA. A total of 1834 AEs were experienced by 53 patients and 281 of these reported by 170 patients were considered as serious. Treatment-related AEs occurring with an incidence of &amp;gt; 2 (specified AE/1000 patient-years) included headache (4.36), myalgia (3.88), peripheral edema (3.88), arthralgia (2.91) and fatigue (2.42) [&lt;ulink linkID="1744563" linkType="Reference"&gt;1744563&lt;/ulink&gt;]. In May 2016, further interim analysis data of 996 patients were presented at ECE 2016 in Munich, Germany. A total of 1772 adverse events (AEs) were reported by 539 patients, including 273 serious AEs. A total of 110 AEs suspected as drug-related were reported by 67 patients [&lt;ulink linkID="1864440" linkType="Reference"&gt;1864440&lt;/ulink&gt;]. In April 2017, further clinical data from 1121 patients were presented at the 99th Endocrine Society Annual Meeting in Orlando, FL. Adverse events resulting in any changes to Omnitrope treatment were few (256/2455; 10.4%). Overall, 80 patients experienced 139 adverse events suspected to be treatment-related. In 17 patients, 26 serious adverse events were recorded as possibly-related to study treatment, including one incidence of diabetes mellitus. None of the ten fatal cases were considered by investigators to be rhGH-treatment related [&lt;ulink linkID="1913177" linkType="Reference"&gt;1913177&lt;/ulink&gt;]. In May 2017, further data of 1121 patients were presented at the 19th ECE in Lisbon, Portugal. A total of 665 patients reported 2455 AEs, including 444 AEs in 247 patients regarded as serious. Of 188 patients who discontinued treatment, 47 were due to an AE [&lt;ulink linkID="1954437" linkType="Reference"&gt;1954437&lt;/ulink&gt;]. In March 2018, further clinical data were presented at100th Endocrine Society Annual Meeting in Chicago, IL. Overall, 3471 AEs were reported in 811 patients; of these, 629 were serious AEs in 25.9% of patients. Most of the reported AEs were found to be mild to moderate in intensity, with an exception of 9.3% of patients in any change to Omnitrope treatment. The suspected drug-related AEs were 150 in 7% of patients. Omnitrope treatment in adults with growth hormone deficiency was found to be well tolerated in a real-life clinical practice setting, both in previously treated and in rhGH-naïve patients [&lt;ulink linkID="2015040" linkType="Reference"&gt;2015040&lt;/ulink&gt;]. In May 2018, similar clinical data were presented at the 20th ECE in Barcelona, Spain [&lt;ulink linkID="2065304" linkType="Reference"&gt;2065304&lt;/ulink&gt;].In March 2019, further interim data were presented at the 2019 Endocrine Society Annual Meeting in New Orleans, LA. Omnitrope was permanently discontinued in a male patient (aged 45 years) with adulthood-onset combined GHD following 4 to 6 months of GH therapy exhibiting diabetes mellitus aggravation. Omnitrope treatment was interrupted in a male patient (aged 72 years) with adulthood-onset combined GHD following 19 years of GH therapy exhibiting diabetes mellitus worsening [&lt;ulink linkID="2131148" linkType="Reference"&gt;2131148&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2006-12-31T00:00:00.000Z</StatusDate><Source id="1309607" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><Source id="1436151" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2008-01-07T00:00:00.000Z</StatusDate><Source id="1350516" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2006-06-17T00:00:00.000Z</StatusDate><Source id="1411505" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2010-12-31T00:00:00.000Z</StatusDate><Source id="1309625" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><Source id="1450511" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><Source id="1466334" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2010-12-31T00:00:00.000Z</StatusDate><Source id="1309668" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2007-01-31T00:00:00.000Z</StatusDate><Source id="1309349" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2010-11-01T00:00:00.000Z</StatusDate><Source id="1596958" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2009-10-05T00:00:00.000Z</StatusDate><Source id="1309607" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2535">Growth hormone deficiency</Indication><StatusDate>2007-01-31T00:00:00.000Z</StatusDate><Source id="1309349" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2006-12-31T00:00:00.000Z</StatusDate><Source id="1309672" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><Source id="1424386" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2010-12-31T00:00:00.000Z</StatusDate><Source id="1309625" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><Source id="1363083" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2890">Prader-Willi syndrome</Indication><StatusDate>2010-11-01T00:00:00.000Z</StatusDate><Source id="1596958" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2006-05-31T00:00:00.000Z</StatusDate><Source id="1309401" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2010-12-31T00:00:00.000Z</StatusDate><Source id="1309625" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><Source id="1454583" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2011-01-01T00:00:00.000Z</StatusDate><Source id="1458539" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2005-11-30T00:00:00.000Z</StatusDate><Source id="661362" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2890">Prader-Willi syndrome</Indication><StatusDate>2013-08-20T00:00:00.000Z</StatusDate><Source id="1477501" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2535">Growth hormone deficiency</Indication><StatusDate>2006-05-31T00:00:00.000Z</StatusDate><Source id="775768" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2006-05-30T00:00:00.000Z</StatusDate><Source id="1484863" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2006-04-12T00:00:00.000Z</StatusDate><Source id="1309367" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2004-09-30T00:00:00.000Z</StatusDate><Source id="661362" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2010-08-30T00:00:00.000Z</StatusDate><Source id="1309349" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2010-08-30T00:00:00.000Z</StatusDate><Source id="1309349" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2009-06-25T00:00:00.000Z</StatusDate><Source id="1317907" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2007-04-20T00:00:00.000Z</StatusDate><Source id="1350516" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2007-07-27T00:00:00.000Z</StatusDate><Source id="1363083" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2007-10-17T00:00:00.000Z</StatusDate><Source id="1451736" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="140">Growth disorder</Indication><StatusDate>2007-09-19T00:00:00.000Z</StatusDate><Source id="1468910" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00889"><Name>Growth hormone receptor</Name><SwissprotNumbers><Swissprot>O46600</Swissprot><Swissprot>P10912</Swissprot><Swissprot>P16310</Swissprot><Swissprot>P16882</Swissprot><Swissprot>P19756</Swissprot><Swissprot>P19941</Swissprot><Swissprot>P79108</Swissprot><Swissprot>P79194</Swissprot><Swissprot>Q02092</Swissprot><Swissprot>Q28575</Swissprot><Swissprot>Q90375</Swissprot><Swissprot>Q95JF2</Swissprot><Swissprot>Q95ML5</Swissprot><Swissprot>Q9JI97</Swissprot><Swissprot>Q9TU69</Swissprot><Swissprot>Q9XSZ1</Swissprot></SwissprotNumbers></Target><Target id="PTGT-04782"><Name>Growth hormone ligand</Name><SwissprotNumbers><Swissprot>O12980</Swissprot><Swissprot>O13188</Swissprot><Swissprot>O18938</Swissprot><Swissprot>O62754</Swissprot><Swissprot>O70615</Swissprot><Swissprot>O73848</Swissprot><Swissprot>O73849</Swissprot><Swissprot>O93566</Swissprot><Swissprot>P01241</Swissprot><Swissprot>P01244</Swissprot><Swissprot>P01245</Swissprot><Swissprot>P01246</Swissprot><Swissprot>P01248</Swissprot><Swissprot>P06880</Swissprot><Swissprot>P07064</Swissprot><Swissprot>P08591</Swissprot><Swissprot>P08899</Swissprot><Swissprot>P08998</Swissprot><Swissprot>P09113</Swissprot><Swissprot>P09537</Swissprot><Swissprot>P09539</Swissprot><Swissprot>P10298</Swissprot><Swissprot>P10607</Swissprot><Swissprot>P10766</Swissprot><Swissprot>P10813</Swissprot><Swissprot>P10814</Swissprot><Swissprot>P11228</Swissprot><Swissprot>P13391</Swissprot><Swissprot>P19795</Swissprot><Swissprot>P20391</Swissprot><Swissprot>P20392</Swissprot><Swissprot>P22077</Swissprot><Swissprot>P24363</Swissprot><Swissprot>P29971</Swissprot><Swissprot>P33092</Swissprot><Swissprot>P33093</Swissprot><Swissprot>P33711</Swissprot><Swissprot>P34005</Swissprot><Swissprot>P34006</Swissprot><Swissprot>P34744</Swissprot><Swissprot>P34745</Swissprot><Swissprot>P34746</Swissprot><Swissprot>P34747</Swissprot><Swissprot>P37885</Swissprot><Swissprot>P37886</Swissprot><Swissprot>P45643</Swissprot><Swissprot>P45654</Swissprot><Swissprot>P45655</Swissprot><Swissprot>P46404</Swissprot><Swissprot>P46407</Swissprot><Swissprot>P48248</Swissprot><Swissprot>P55755</Swissprot><Swissprot>P56437</Swissprot><Swissprot>P58343</Swissprot><Swissprot>P58756</Swissprot><Swissprot>P67930</Swissprot><Swissprot>P67931</Swissprot><Swissprot>P69158</Swissprot><Swissprot>P69159</Swissprot><Swissprot>P69160</Swissprot><Swissprot>P69161</Swissprot><Swissprot>P69162</Swissprot><Swissprot>P79885</Swissprot><Swissprot>P87391</Swissprot><Swissprot>Q01282</Swissprot><Swissprot>Q01283</Swissprot><Swissprot>Q05163</Swissprot><Swissprot>Q07221</Swissprot><Swissprot>Q1HFN3</Swissprot><Swissprot>Q659Q8</Swissprot><Swissprot>Q7YQB8</Swissprot><Swissprot>Q7YQD2</Swissprot><Swissprot>Q7YRR6</Swissprot><Swissprot>Q864S7</Swissprot><Swissprot>Q8HYE5</Swissprot><Swissprot>Q8MI73</Swissprot><Swissprot>Q98UF6</Swissprot><Swissprot>Q9DEV3</Swissprot><Swissprot>Q9DGG5</Swissprot><Swissprot>Q9GKA1</Swissprot><Swissprot>Q9GL60</Swissprot><Swissprot>Q9GMB2</Swissprot><Swissprot>Q9GMB3</Swissprot><Swissprot>Q9I9L5</Swissprot><Swissprot>Q9I9M4</Swissprot><Swissprot>Q9IB11</Swissprot><Swissprot>Q9IBE5</Swissprot><Swissprot>Q9JKM4</Swissprot><Swissprot>Q9PWG3</Swissprot><Swissprot>Q9W6J5</Swissprot><Swissprot>Q9W6J7</Swissprot><Swissprot>Q9W6R8</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2160688" linkType="reference" linkID="2160688"&gt;2160688&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="30972">Nipro Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="136047" title="Sandoz and Nipro to cross-license and codevelop somatropin BS in Japan"/></Deals><PatentFamilies><PatentFamily id="1531673" number="WO-2005019466" title="Process for the preparation of recombinant polypeptides"/><PatentFamily id="1585732" number="WO-2005017174" title="Process for the purification of recombinant polypeptides"/><PatentFamily id="2102817" number="WO-2004004779" title="Liquid formulations with a high concentration of human growth hormone (hGH) comprising glycine"/><PatentFamily id="2195788" number="WO-00103741" title="Growth hormone formulations"/><PatentFamily id="2462485" number="WO-2013014196" title="Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein"/><PatentFamily id="326022" number="WO-02067989" title="Crystallisation-resistant aqueous growth hormone formulations"/><PatentFamily id="742936" number="WO-2009130048" title="Stabilized liquid formulation"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="JDS Consulting" id="1006525"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Altus Pharmaceuticals Inc" id="20740"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>7</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nipro Corp" id="30972"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>